BACKGROUND: A previous RTS,S/AS01B vaccine challenge trial demonstrated that a 3-dose (0-1-7-month) regimen with a fractional third dose can produce high vaccine efficacy (VE) in adults challenged 3 weeks after vaccination. This study explored the VE of different delayed fractional dose regimens of adult and pediatric RTS,S/AS01 formulations. METHODS: A total of 130 participants were randomized into 5 groups. Four groups received 3 doses of RTS,S/AS01B or RTS,S/AS01E on a 0-1-7-month schedule, with the final 1 or 2 doses being fractional (one-fifth dose volume). One group received 1 full (month 0) and 1 fractional (month 7) dose of RTS,S/AS01E. Immunized and unvaccinated control participants underwent Plasmodium falciparum-infected mosquito challenge (controlled human malaria infection) 3 months after immunization, a timing chosen to potentially discriminate VEs between groups. RESULTS: The VE of 3-dose formulations ranged from 55% (95% confidence interval, 27%-72%) to 76% (48%-89%). Groups administered equivalent formulations of RTS,S/AS01E and RTS,S/AS01B demonstrated comparable VE. The 2-dose group demonstrated lower VE (29% [95% confidence interval, 6%-46%]). All regimens were well tolerated and immunogenic, with trends toward higher anti-circumsporozoite antibody titers in participants protected against infection. CONCLUSIONS: RTS,S/AS01E can provide VE comparable to an equivalent RTS,S/AS01B regimen in adults, suggesting a universal formulation may be considered. Results also suggest that the 2-dose regimen is inferior to the 3-dose regimens evaluated. CLINICAL TRIAL REGISTRATION: NCT03162614.
RCT Entities:
BACKGROUND: A previous RTS,S/AS01B vaccine challenge trial demonstrated that a 3-dose (0-1-7-month) regimen with a fractional third dose can produce high vaccine efficacy (VE) in adults challenged 3 weeks after vaccination. This study explored the VE of different delayed fractional dose regimens of adult and pediatric RTS,S/AS01 formulations. METHODS: A total of 130 participants were randomized into 5 groups. Four groups received 3 doses of RTS,S/AS01B or RTS,S/AS01E on a 0-1-7-month schedule, with the final 1 or 2 doses being fractional (one-fifth dose volume). One group received 1 full (month 0) and 1 fractional (month 7) dose of RTS,S/AS01E. Immunized and unvaccinated control participants underwent Plasmodium falciparum-infected mosquito challenge (controlled humanmalaria infection) 3 months after immunization, a timing chosen to potentially discriminate VEs between groups. RESULTS: The VE of 3-dose formulations ranged from 55% (95% confidence interval, 27%-72%) to 76% (48%-89%). Groups administered equivalent formulations of RTS,S/AS01E and RTS,S/AS01B demonstrated comparable VE. The 2-dose group demonstrated lower VE (29% [95% confidence interval, 6%-46%]). All regimens were well tolerated and immunogenic, with trends toward higher anti-circumsporozoite antibody titers in participants protected against infection. CONCLUSIONS:RTS,S/AS01E can provide VE comparable to an equivalent RTS,S/AS01B regimen in adults, suggesting a universal formulation may be considered. Results also suggest that the 2-dose regimen is inferior to the 3-dose regimens evaluated. CLINICAL TRIAL REGISTRATION: NCT03162614.
Authors: Richard T Kenney; Sarah A Frech; Larry R Muenz; Christina P Villar; Gregory M Glenn Journal: N Engl J Med Date: 2004-11-03 Impact factor: 91.245
Authors: Kent E Kester; James F Cummings; Opokua Ofori-Anyinam; Christian F Ockenhouse; Urszula Krzych; Philippe Moris; Robert Schwenk; Robin A Nielsen; Zufan Debebe; Evgeny Pinelis; Laure Juompan; Jack Williams; Megan Dowler; V Ann Stewart; Robert A Wirtz; Marie-Claude Dubois; Marc Lievens; Joe Cohen; W Ripley Ballou; D Gray Heppner Journal: J Infect Dis Date: 2009-08-01 Impact factor: 5.226
Authors: J A Stoute; M Slaoui; D G Heppner; P Momin; K E Kester; P Desmons; B T Wellde; N Garçon; U Krzych; M Marchand Journal: N Engl J Med Date: 1997-01-09 Impact factor: 91.245
Authors: D M Gordon; T W McGovern; U Krzych; J C Cohen; I Schneider; R LaChance; D G Heppner; G Yuan; M Hollingdale; M Slaoui Journal: J Infect Dis Date: 1995-06 Impact factor: 5.226
Authors: Jason A Regules; Susan B Cicatelli; Jason W Bennett; Kristopher M Paolino; Patrick S Twomey; James E Moon; April K Kathcart; Kevin D Hauns; Jack L Komisar; Aziz N Qabar; Silas A Davidson; Sheetij Dutta; Matthew E Griffith; Charles D Magee; Mariusz Wojnarski; Jeffrey R Livezey; Adrian T Kress; Paige E Waterman; Erik Jongert; Ulrike Wille-Reece; Wayne Volkmuth; Daniel Emerling; William H Robinson; Marc Lievens; Danielle Morelle; Cynthia K Lee; Bebi Yassin-Rajkumar; Richard Weltzin; Joe Cohen; Robert M Paris; Norman C Waters; Ashley J Birkett; David C Kaslow; W Ripley Ballou; Christian F Ockenhouse; Johan Vekemans Journal: J Infect Dis Date: 2016-06-13 Impact factor: 5.226
Authors: Michael T White; Robert Verity; Jamie T Griffin; Kwaku Poku Asante; Seth Owusu-Agyei; Brian Greenwood; Chris Drakeley; Samwel Gesase; John Lusingu; Daniel Ansong; Samuel Adjei; Tsiri Agbenyega; Bernhards Ogutu; Lucas Otieno; Walter Otieno; Selidji T Agnandji; Bertrand Lell; Peter Kremsner; Irving Hoffman; Francis Martinson; Portia Kamthunzu; Halidou Tinto; Innocent Valea; Hermann Sorgho; Martina Oneko; Kephas Otieno; Mary J Hamel; Nahya Salim; Ali Mtoro; Salim Abdulla; Pedro Aide; Jahit Sacarlal; John J Aponte; Patricia Njuguna; Kevin Marsh; Philip Bejon; Eleanor M Riley; Azra C Ghani Journal: Lancet Infect Dis Date: 2015-09-02 Impact factor: 25.071
Authors: DeAnna J Friedman-Klabanoff; Andrea A Berry; Mark A Travassos; Catherine Cox; Yingjun Zhou; Annie X Mo; Effie Y H Nomicos; Gregory A Deye; Marcela F Pasetti; Matthew B Laurens Journal: Vaccine Date: 2021-01-22 Impact factor: 4.169
Authors: Aaron M Samuels; Daniel Ansong; Simon K Kariuki; Samuel Adjei; Anne Bollaerts; Christian Ockenhouse; Nelli Westercamp; Cynthia K Lee; Lode Schuerman; Dennis K Bii; Lawrence Osei-Tutu; Martina Oneko; Marc Lievens; Maame Anima Attobrah Sarfo; Cecilia Atieno; Danielle Morelle; Ashura Bakari; Tony Sang; Erik Jongert; Maame Fremah Kotoh-Mortty; Kephas Otieno; François Roman; Patrick Boakye Yiadom Buabeng; Yaw Ntiamoah; Opokua Ofori-Anyinam; Tsiri Agbenyega Journal: Lancet Infect Dis Date: 2022-06-23 Impact factor: 71.421